Morphological Transformation and Phosphatidylserine Exposure in Erythrocytes Treated with Ribavirin

被引:12
作者
Homma, Masato [1 ,2 ]
Hosono, Hiroyuki [1 ]
Hasegawa, Yuichi [3 ]
Kohda, Yukinao [1 ,2 ]
机构
[1] Tsukuba Univ Hosp, Dept Pharm, Tsukuba, Ibaraki 3058576, Japan
[2] Univ Tsukuba, Dept Pharmaceut Sci, Tsukuba, Ibaraki 3058575, Japan
[3] Univ Tsukuba, Grad Sch Comprehens Human Sci, Dept Hematol, Tsukuba, Ibaraki 3058575, Japan
关键词
ribavirin; erythrocyte; phosphatidylserine exposure; morphological transformation; CHRONIC HEPATITIS-C; MEMBRANE PHOSPHOLIPID ASYMMETRY; INITIAL TREATMENT; HEMOLYTIC-ANEMIA; APOPTOTIC CELLS; PLUS RIBAVIRIN; RECEPTOR; INTERFERON-ALPHA-2B; THERAPY; BLOOD;
D O I
10.1248/bpb.32.1940
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The effects of intracellular ribavirin on morphology and redistribution of phosphatidylserine (PS) in human erythrocytes were examined. Erythrocytes were incubated with I mM ribavirin in the presence/absence of dipyridamole, an inhibitor of es-type nucleoside transporter. Intracellular ribavirin was accumulated in erythrocytes with the concentration of 1361 mu M, which corresponds to the blood level in patients receiving ribavirin. Dipyridamole reduced ribavirin accumulation by 40.7% (807 mu M) via inhibiting es-type nucleoside transporter on erythrocytes. Morphological transformation into echinocytic form was observed in 86.4% of the erythrocytes treated with ribavirin. Dipyridamole pre-treatment decreased the morphological change to 20.0%. Ribavirin increased the PS-exposing cells compared with control (2.15%) vs. 0.87%). PS-exposing cells were also decreased by inhibiting ribavirin accumulation with dipyridamole (0.62%). The results suggest that intracellular ribavirin induces morphological change and PS exposure in erythrocytes and accelerates erythrophagocytosis in the reticuloendothelial system.
引用
收藏
页码:1940 / 1942
页数:3
相关论文
共 26 条
[1]  
BACKMAN L, 1986, J CELL SCI, V80, P281
[2]  
Bonomini M, 1999, J AM SOC NEPHROL, V10, P1982
[3]   Meta-analysis: ribavirin-induced haemolytic anaemia in patients with chronic hepatitis C [J].
Chang, CH ;
Chen, KY ;
Lai, MY ;
Chan, KA .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2002, 16 (09) :1623-1632
[4]   Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: Role of membrane oxidative damage [J].
De Franceschi, L ;
Fattovich, G ;
Turrini, F ;
Ayi, K ;
Brugnara, C ;
Manzato, F ;
Noventa, F ;
Stanzial, AM ;
Solero, P ;
Corrocher, R .
HEPATOLOGY, 2000, 31 (04) :997-1004
[5]   A receptor for phosphatidylserine-specific clearance of apoptotic cells [J].
Fadok, VA ;
Bratton, DL ;
Rose, DM ;
Pearson, A ;
Ezekewitz, RAB ;
Henson, PM .
NATURE, 2000, 405 (6782) :85-90
[6]   Side effects of therapy of hepatitis C and their management [J].
Fried, MW .
HEPATOLOGY, 2002, 36 (05) :S237-S244
[7]   Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre survey in 'real world' patients with chronic hepatitis C [J].
Gaeta, GB ;
Precone, DF ;
Felaco, FM ;
Bruno, R ;
Spadaro, A ;
Stornaiuolo, G ;
Stanzione, M ;
Ascione, T ;
De Sena, R ;
Campanone, A ;
Filice, G ;
Piccinino, F .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2002, 16 (09) :1633-1639
[8]   High-performance liquid chromatographic determination of ribavirin in whole blood to assess disposition in erythrocytes [J].
Homma, M ;
Jayewardene, AL ;
Gambertoglio, J ;
Aweeka, F .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (11) :2716-2719
[9]   Marked Elevation of Erythrocyte Ribavirin Levels in Interferon and Ribavirin-Induced Anemia [J].
Homma, Masato ;
Matsuzaki, Yasushi ;
Inoue, Yoichi ;
Shibata, Minoru ;
Mitamura, Keiji ;
Tanaka, Naomi ;
Kohda, Yukinao .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2004, 2 (04) :337-339
[10]   Erythrocyte ribavirin concentration for assessing hemoglobin reduction in interferon and ribavirin combination therapy [J].
Inoue, Y ;
Homma, M ;
Matsuzaki, Y ;
Shibata, M ;
Matsumura, T ;
Ito, T ;
Kohda, Y .
HEPATOLOGY RESEARCH, 2006, 34 (01) :23-27